Manufacturer of Controlled Substances; Notice of Application, 2907 [E7-850]

Download as PDF Federal Register / Vol. 72, No. 14 / Tuesday, January 23, 2007 / Notices DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 21, 2006, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Remifentanil (9739) ...................... I I II II II II II II II mstockstill on PROD1PC70 with NOTICES The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 26, 2007. Dated: January 16, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–850 Filed 1–22–07; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 19:33 Jan 22, 2007 Jkt 211001 Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 20, 2006, Organix Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in schedule II. The company plans on manufacturing this controlled substance for sale to its customers. These customers will sell the drug in small quantities for research purposes or as drug standards for forensic laboratories. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 26, 2007. Dated: January 16, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–851 Filed 1–22–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 a.m. to 4:30 p.m. on Monday, February 26, 2007. 8 a.m. to 4:30 p.m. on Tuesday, February 27, 2007. Place: American Correctional Association, 206 North Washington Street, Suite 200, Alexandria, Virginia 22314, 1 (800) 222–5646. Status: Open. Matters to be Considered: Reports; Faith Based; Mental health; Prison Rape PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 2907 Elimination Act (PREA) Update; Agency reports; Quarterly Report by Office of Justice Programs. Contact Person for More Information: Larry Solomon, Deputy Director, 202– 307–3106, ext. 44254. Morris L. Thigpen, Director. [FR Doc. 07–255 Filed 1–22–07; 8:45 am] BILLING CODE 4410–30–M NUCLEAR REGULATORY COMMISSION Agency Information Collection Activities: Proposed Collection: Comment Request U.S. Nuclear Regulatory Commission (NRC). ACTION: Notice of pending NRC action to submit an information collection request to OMB and solicitation of public comment. AGENCY: SUMMARY: The NRC is preparing a submittal to OMB for review of continued approval of information collections under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). Information Pertaining to the Requirement To Be Submitted 1. The title of the information collection: NRC Form 314, Certificate of Disposition of Materials. 2. Current OMB approval numbers: 3150–0028. 3. How often the collection is required: The form is submitted once, when a licensee terminates its license. 4. Who is required or asked to report: Persons holding an NRC license for the possession and use of radioactive byproduct, source, or special nuclear material who are ceasing licensed activities and terminating the license. 5. The estimated number of annual respondents: 171. 6. The number of hours needed annually to complete the requirement or request: 85.5. 7. Abstract: NRC Form 314 furnishes information to NRC regarding transfer or other disposition of radioactive material by licensees who wish to terminate their licenses. The information is used by NRC as part of the basis for its determination that the facility has been cleared of radioactive material before the facility is released for unrestricted use. Submit, by March 26, 2007, comments that address the following questions: 1. Is the proposed collection of information necessary for the NRC to E:\FR\FM\23JAN1.SGM 23JAN1

Agencies

[Federal Register Volume 72, Number 14 (Tuesday, January 23, 2007)]
[Notices]
[Page 2907]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-850]



[[Page 2907]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 21, 2006, Cedarburg 
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
Remifentanil (9739)........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than March 26, 2007.

    Dated: January 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-850 Filed 1-22-07; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.